Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00294502
Recruitment Status : Completed
First Posted : February 22, 2006
Last Update Posted : February 22, 2006
Information provided by:
Henry Ford Health System

Brief Summary:
To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.

Condition or disease Intervention/treatment Phase
ESRD Drug: Gentamycin/citrate, Minocycline/EDTA Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Study Start Date : September 2003
Estimated Study Completion Date : May 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Incidence of symptomatic CRB

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ESRD patients with tunnelled catheters

Exclusion Criteria:

  • patients on IV abx for infections, patients who have AV graft, AV fistulas

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00294502

United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Principal Investigator: Antanole Bearabe, MD Henry Ford Hospital

Publications of Results: Identifier: NCT00294502     History of Changes
Other Study ID Numbers: 3008
First Posted: February 22, 2006    Key Record Dates
Last Update Posted: February 22, 2006
Last Verified: September 2003

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action